What is VitriVax?
VitriVax operates at the intersection of biotechnology and global health, specializing in the development of thermostable, single-dose vaccines. Its core innovation, the ALTA technology platform, is designed to eliminate the cold-chain requirements that currently hinder vaccine delivery in resource-limited settings. By stabilizing vaccine formulations, VitriVax aims to significantly improve global accessibility and ensure that life-saving immunizations reach underserved populations without the logistical constraints of traditional refrigeration. This market position places the company as a critical player in the future of public health infrastructure.
How much funding has VitriVax raised?
VitriVax has raised a total of $22.3M across 2 funding rounds:
Grant
$5M
Series B
$17.3M
Grant (2023): $5M with participation from Bill & Melinda Gates Foundation
Series B (2025): $17.3M led by Adjuvant Capital and RA Capital Management
Key Investors in VitriVax
Adjuvant Capital
Adjuvant Capital is a venture capital firm focused on financing innovative life science technologies that address high-burden public health challenges, emphasizing both social and financial returns.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing its TechAtlas think tank to guide strategic decisions.
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation is a global philanthropic organization dedicated to supporting individuals experiencing hunger and extreme poverty in leading healthier lives through strategic health investments.
What's next for VitriVax?
With the successful closure of this major enterprise-level funding, VitriVax is poised to enter a phase of accelerated clinical validation and operational scaling. The strategic focus will likely shift toward optimizing the manufacturing processes for its ALTA-enabled products and expanding its pipeline to address a wider array of infectious diseases. As the company leverages this capital, it will prioritize the transition of its lead candidates from laboratory settings to clinical trials, aiming to demonstrate the real-world efficacy of its thermostable solutions. The continued support from specialized life science investors suggests a long-term commitment to achieving both significant public health impact and sustainable commercial growth.
See full VitriVax company page
